Inhaled Nitric Oxide for Preventing Progression in COVID-19
Status:
Terminated
Trial end date:
2020-11-23
Target enrollment:
Participant gender:
Summary
This is a pilot randomized-controlled (2:1) open label investigation of inhaled NO to prevent
progression to more advanced disease in 42 hospitalized patients with COVID-19, at risk for
worsening, based on baseline systemic oxygenation and 2 or more of the major risk factors of
age > 60 years, type II DM, hypertension, and obesity.